CUDC-907: Phase I started

Curis began an open-label, U.S. Phase I trial to evaluate 3 dosing

Read the full 127 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE